Bayer: Hypertension, Pulmonary trials

The registry lists 38 Hypertension, Pulmonary studies with Bayer as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 5Phase 2 7Phase 3 8Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Riociguat in Children With Pulmonary Arterial Hypertension (PAH)Active, not recruitingNCT02562235Phase 3Results posted
• Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)CompletedNCT02191137Phase 4Results posted
• Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.CompletedNCT01179334Phase 2Results posted
• A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic DysfunctionTerminatedNCT01065454Phase 2Results posted
• Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation KineticsTerminatedNCT01065051Phase 2Results posted
• BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary HypertensionCompletedNCT00910429Phase 3Results posted
• BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial HypertensionCompletedNCT00863681Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.CompletedNCT00855465Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00810693Phase 3Results posted
• Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.CompletedNCT00640315Phase 1Results posted
• A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)CompletedNCT06048120Phase 1
• This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedNCT03754660Phase 1
• Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial HypertensionCompletedNCT03293407
• Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)CompletedNCT02826252
• Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)CompletedNCT02825160
• A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.CompletedNCT02759419Phase 4
• A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA CountriesCompletedNCT02637050
• Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)CompletedNCT02576002
• A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical PracticeCompletedNCT02545465
• Electronic Activity Level Monitoring Pilot in Pulmonary HypertensionCompletedNCT02536534
• Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)CompletedNCT02428985
• Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )CompletedNCT02117791
• EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary HypertensionCompletedNCT02092818
• Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 InhibitorCompletedNCT02007629Phase 3
• Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary HypertensionCompletedNCT01971450
• Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for InhalationCompletedNCT01894035
• Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)No longer availableNCT01784562
• Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation StudyCompletedNCT01469169Phase 3
• Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 YearsCompletedNCT01389271
• A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic DysfunctionTerminatedNCT01172756Phase 2
• Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)CompletedNCT01062282
• Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)CompletedNCT00694850Phase 2
• Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TIDCompletedNCT00680654Phase 1
• Single Dose Escalation Study in Patients With Chronic Heart FailureCompletedNCT00565565Phase 1
• An Open Multiple Dose Titration Study In Patients With Pulmonary HypertensionCompletedNCT00454558Phase 2
• Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary HypertensionCompletedNCT00414687Phase 2
• Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 YearsCompletedNCT00250640
• Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary HypertensionCompletedNCT00185315Phase 3